


Servier Pipeline

January 2024



SERVIER 
moved by you



Oncology – solid tumors

Compound / MOA	Project	Therapeutic Area	Territory	Phase	Partner
Vorasidenib	S95032	Low grade Glioma with IDH1/2 mutation	Worldwide	PCD 1 2 3	
Ivosidenib	S95031	Solid tumors (new indication)	Worldwide	PCD 1 2 3	
Anti-MET	S95027	Non small Cell Lung Cancer	Worldwide	PCD 1 2 3	
Vorasidenib + pembrolizumab	S95032	Grade 2-3 Glioma with IDH1/2 mutation	Worldwide	PCD 1/2 3	
Ivosidenib combo	S95031	Solid tumors (new indication)	Worldwide	PCD 1/2 3	
Anti-TIM3 combo	S95018	Solid tumors	Worldwide	PCD 1/2 3	
Anti-CD73 combo	S95024	Solid tumors	Worldwide	PCD 1/2 3	
Anti-PD-L1/4-1BB	S95012	Solid tumors	Worldwide	PCD 1/2 3	
Anti-NKG2A combo	S95029	Solid tumors	Worldwide	PCD 1/2 3	
MAT2A inhibitor	S95035	Solid tumors	Worldwide	PCD 1/2 3	
ND	S95043	Solid tumors	Worldwide	PCD 1 2 3	

PCD = Preclinical development phase, 1 = Phase 1, 2 = Phase 2,
3 = Phase 3, MOA = Mode of action, ND= Not disclosed

Data as of January 2024

Oncology – Hematological malignancies


Compound / MOA	Project	Therapeutic Area	Territory	Phase				Partner
Ivosidenib combo 7+3 (chemo)	S95031	Hematological malignancies (new indication)	Worldwide	PCD	1	2	3	
Calaspargase pegol combo	S95015	Hematological malignancies (new indication)	Worldwide	PCD	1	2	3	
BCL-2 inhibitor + azacitidine	S65487	1st line Acute Myeloid Leukemia (AML)	Worldwide	PCD	1/2		3	
ND	S227928	Hematological malignancies	Worldwide	PCD	1	2	3	

Data as of January 2024

PCD = Preclinical development phase, 1 = Phase 1, 2 = Phase 2,
3 = Phase 3, MOA = Mode of action, ND= Not disclosed

Neuroscience and immuno-inflammation

NEUROSCIENCE

Compound / MOA	Project	Therapeutic Area	Territory	Phase	Partner
LRRK2 inhibitor	S221237	Parkinson's disease	Worldwide	<div><div>PCD</div><div>1</div><div>2</div><div>3</div></div>	
ND	S230815	Neurodevelopmental disorder	Worldwide	<div><div>PCD</div><div>1</div><div>2</div><div>3</div></div>	

IMMUNO-INFLAMMATION

Compound / MOA	Project	Therapeutic Area	Territory	Phase	Partner
ND	S95041	Autoimmune disease	Worldwide	<div><div>PCD</div><div>1</div><div>2</div><div>3</div></div>	
ND	S95042	Autoimmune disease	Worldwide	<div><div>PCD</div><div>1</div><div>2</div><div>3</div></div>	

Data as of January 2024

PCD = Preclinical development phase, 1 = Phase 1, 2 = Phase 2,
3 = Phase 3, MOA = Mode of action, ND= Not disclosed

